8th PATIENT CENTRICITY & COLLABORATION WORLD CONGRESS 2026 EUROPE
A strategic approach prioritising the patient's needs, preferences, and values from drug development to treatment and beyond.
Hilton London Kensington, London, United Kingdom
Tuesday 25th - Wednesday 26th February 2026
We are delighted to invite you to the 8th Patient Centricity and Collaboration World Congress 2026 Europe, hosted by Facilitate Live. This two-day Congress aims to foster meaningful collaborations among industry professionals, advocacy groups, clinicians, researchers, and, most importantly, patients and their caregivers. You will have the opportunity to acquire practical strategies and best practices for addressing challenges, embracing innovations, utilising new technologies, and implementing concepts that contribute to achieving patient-centric goals.
The congress theme, “A strategic approach prioritising the patient’s needs, preferences, and values from drug development to treatment and beyond,” underscores the critical importance of patient centricity and engagement in biopharmaceutical research and development, disease management, and the design of treatments, clinical trials, and other health solutions. True patient-centric solutions necessitate a collaborative endeavor with patients and their caregivers, involving their feedback and insights into medical conditions, experiences, needs, perspectives, and priorities.
Patient centricity necessitates a departure from traditional approaches, embracing diverse, patient centered perspectives. This involves several key aspects, beginning with patient-centric clinical trials and drug development, integrating patient insights into the design, evaluation, and manufacturing of therapeutic products. It also entails actively engaging patients in discussions and decisions concerning healthcare products and services. Patient centricity further emphasizes personalized care, tailoring treatments, communications, and support to individual patient needs. This is complemented by improved communication, fostering clear, transparent, and accessible interactions between healthcare professionals and patients. Ultimately, patient centricity extends to prioritizing patient well-being, acknowledging emotional, social, and financial considerations alongside medical conditions.
While technology-driven advancements present challenges, they also create opportunities to enhance the patient experience by coordinating the health ecosystem around the patient. This requires reevaluating drug development and delivery to improve experiences and outcomes, and continuously adapting to meet the evolving needs of patients.
The industry has made significant progress in adopting a patient centered approach, transforming the concept from a mere buzzword to a tangible goal. However, with the evolving healthcare model and ecosystem, driven by technological advancements and more engaged patients, achieving true patient centricity remains an ongoing quest and a steadfast commitment.
We look forward to meeting you at the Congress!
Sincerely yours,
Jocelyn Raguindin
Conference Director
Paradigm Global Events / Facilitate Live
GAIN LATEST INSIGHTS ON:
- Critical topics regarding patient centricity within the pharmaceutical and life sciences industry.
- Why it’s imperative for our industry to fully embrace the patient-centric movement?
- We will delve into several key areas that are vital for its successful implementation.
- We will be exploring what patient centricity truly means for our sector.
- Why it’s so crucial for the industry to actively participate in this shift?
- Patient-centric initiatives that have already demonstrated a significant impact.
- Successful strategies and best practices for managing patient centricity in healthcare.
- How we can develop and execute effective strategies to improve patient engagement and the benefits this engagement brings to the drug development and
discovery process. - Evolving challenges and key considerations in the ethical and compliant use of relevant data, and the potential value of providing access to this data to all stakeholders.
- How we can maintain mutually beneficial ongoing partnerships between patients and the industry. Overcoming the challenges in making clinical trials and drug development more patient-centered.
- Setting expectations through collaborations
- Understanding the role of researchers in bridging communication gaps.
- This congress also focuses on practical strategies for developing a powerful brand with the patient at its core.
Co-located with the Decentralized & Hybrid Trials 2026 Europe
WHO SHOULD ATTEND?
This Congress is beneficial to pharmaceutical, biotech companies, researchers, physicians, patient advocacy groups, regulatory agencies, technology and healthcare companies.
Network with Presidents, Heads/Chiefs, VPs, Directors, and Leaders in the area of:
- Patient Engagement
- Patient Services
- Engagement Strategy
- R&D Patient Engagement
- Medical Affairs
- Commercialisation
- Marketing
- Regulatory Affairs and Policy
- Patient Support
- RWE, and Data Management
- Quality and Compliance
- Clinical Development and Operations
- Programme Management
- Supply Chain Management
- Patient Access
- Clinical Research
- Digital Accelerator
- Patient Engagement & Portfolio Strategy
- Patient Support
- Strategy & Insights
- Patient Experience
- Global Patient Advocacy & Alliances
- Government Policy and Advocacy
- Digital Patient Experience Lead
- Clinical Insights and Experience
- Head of Strategy, Access Services
- Site Collaborations and Patient Centricity
Hayley Chapman, Senior Program Director, The Synergist
TRENDS & STRATEGIES IN PATIENT CENTRICITY AND COLLABORATION
- What are the main internal and external barriers to achieving genuine patient centricity?
- What are the key elements for creating an authentically patient-centric company culture?
- What are the challenges and opportunities in shifting to a patient-centric mindset?
- How can a patient-centric culture improve patient access and transparency?
- How can patients be meaningfully involved in the drug development process, from early research to post market surveillance?
Moderator:
Panelists:
Tom Croce, Vice President, Global Patient Advocacy, Jazz Pharmaceuticals
Carole Scrafton, Director & Co-Founder, Flutters and Strutters
Nadya Isack, PPIE Advocate, Person living with Obesity, Founder, Empower Health Initiative
- Many biotech/pharmaceutical companies are talking about ”Patient Centricity”, but how can a company actually operate in a patient-centric way to create meaningful value?
- Learn best practices to transition from being product centered to patient centered
- Discuss strategies to embed patient centricity throughout your organization.
Gabor Purman, Patient Advocacy Director, Kyowa Kirin
The three acts of dignity by design
- The human imperative why dignity must be our north star. Without dignity engagement becomes more transaction than a true sustainable partnership
- The systemic challenges and why intentions are not good enough: Moving away from piloting endlessly to institutionalizing proactively. Pilots miss the three pillars of trust, transparency and equity
- The future by Design: the right blueprint for meaningful sustainable partnerships
Ify Osunkwo, Chief Patient Officer Rare Disease, Novo Nordisk Rare Disease
- Patient Centricity requires new mindsets, relationships – and structures, company-wide. No stage of development, from discovery through delivery, gets a pass.
- No company function continues as before. Company culture changes, too.
- This isn’t easy but the results are worth the journey: to improve outcomesfor patients and business performance alike.
- If Patient Centricity is a fad, then it’s a failure.It should be the new way of doing business.
Lawrence Tallon, Chief Executive Officer, MHRA
- Understanding complexities and addressing challenges faced by the industry in setting up end-to end supply chain for cell and gene therapies
- Best practices and lessons learnedthat guarantees effective manufacturing and deliveryof CGTs to the patients who needs them the most
- Robust technologies and innovative platformsthat connects therapieswith patients both in clinicaland commercial scale
RESERVED: Awaiting for Materials
- The NIHR partners with over 100 charities and community groups when recruiting to its public involvement activities.
- This has increased the numbers, diversity and representativeness of the public who take part in PPIE activities, including the often overlooked ‘research naive’ voice.
- Our challenge is how we continue to develop these partnerships in a fair and reciprocal manner, bringing benefit to all involved.
Emily Pickering, Specialist Commercial Services Lead, Patient Engagement in Clinical Development, NIHR Research Delivery Network
Isabella Darbyshire, Specialist Commercial Services Manager, Patient Engagement in Clinical Development, NIHR Research Delivery Network
- Understand where patientcentricity can advancethe interests sharedby industry and the patientcommunity Consider how focused goals and programs can strengthen research and development, commercialization and access
- Focus on opportunities to integrate patients,caregivers, consumers and advocates’ key concerns and insights into company plans and decision making
- Discuss applications of this targeted approach to your patient centricity goals and programs
Afternoon Stream Sessions
ACCESS & COLLABORATION
Gunnar Philipp, Head of Medical Affairs Europe MajorMarkets and Canada, CSL
- Co-creating an innovative methodology
- Designing meaningful research tools
- Partnering for local impact
- Collaborative validation
- Co-creating the GENS publication
Claire Nolan, Head of Engagement, International Bureau for Epilepsy
- Across the spectrum of disease, from common to
rare,patient data is becoming a critical driver of
drug discovery, development, diagnosis,
commercialization and inclusive and equitable
access to trials and treatments.
- This resolution is not just symbolic. It provides a concrete, evidence-backed roadmap for engaging patients, people with lived experience, healthcare providers, and civil society in a structured, measurable, accountable and resourced way in health system design, delivery and decision making. It is an opportunity to reshift focus on the health outcomes that matter –too often health is done to people, not with people. And it’s an opportunity for the patient community to claim its
space once and for all.
Amanda Bok, Chief Partnership Officer, The Synergist
- Common barriers to access
- Strategies to address barriers to access
Josie Godfrey, Co-Founder and CEO, Realise Advocacy
- To raise awareness of how digital literacy gaps fuel health inequalities across Europe.
- To show why pharma has a stake in closing this divide — for better patient outcomes, trust, and equitable access
- To share practical strategies and partnerships where pharma can lead, influence, and innovate responsibly.
Becky Warnes, Public Affairs and NHS Liaison
Manager, Orion Pharma UK Ltd
- The illusion of inclusion
- What transformation looks like
- The cost of exclusion
- Creating space for truth and trust
- Why this matters for you?
Daniel Newman, Patient Advocate, Trueheart
International
- Roles and responsibilities in achieving positive outcomes
- Key learnings from the evolving process
- Guiding principles for future partnerships.
Steve Clark, Founder , Strive for Five
CLINICAL RESEARCH & TECHNOLOGY
Robert Mitchell-Thain, CEO, PBC Foundation
- Reconsider terminology to reframe activity
- Prioritise engagement that leads to involvement and subsequent participation (listen-ask-invite)
- Shift thinking from ‘patient’ involvement to ‘potential participant’ involvement (PPIE becomes EIPP)
- Invest in ‘foresight’ as a valuable commodity
Lorna Allen, Senior Involvement Manager, Cystic Fibrosis Trust
- Patients and caregivers know best when it means improving the quality of life.
- Reality is much different than theory.
- Benefits of real-world experience inserted in basic science equals endpoints and outcomes that can be overlooked as unimportant.
Allocated: Awaiting for Materials – Details Available Shortly.
- Why patient voice matters: shifting from researcher- centric to participant-driven research design.
- The challenge today: trials often start late, and participants struggle to find relevant opportunities — a reality our platform helps address.
- How The Patient Voice Database works: simple profile creation, matching to relevant opportunities, full control and consent for participants.
- Key benefits: for patients (access, control), and for researchers (better recruitment, representativeness, efficiency).
- Practical examples and early results: Belgium as pilot country; thousands registered; next steps for broader deployment.
Jean-Sébastien Gosuin, Founder, Curewiki
- Contributions that advocacy group scan make to clinical trial development
- The importance of knowing the people, their disease, and its burdens
- Successful collaborations are a win for all
Greg Robertson, Sr Director, Patient Advocacy, Global Rare & Clinical Dev’t., Alnylam
- Addressing logistical challenges crucial for better participation and retention
- Enhance reported outcome measures and quality of-life assessments
Allocated Awaiting for Materials – Available Shortly.
- Why the vast majority of clinical trials run into
problems of recruiting participants - What you can do to solve these issues and improve
your overall recruitment strategy - This presenation will include a mix of case studies,
real world examples from different clinical trials and
provide specific to do’s to improve the patient
recruitment for your clinical trial.
Rasmus Hjorth, Patient Engagement Director, James
Lind Care
- Layering patient generated health data with clinical data
- Building insights across all diverse patient profiles
- Move beyond evidence for clinical trial participants only
Mark Bradley, CEO, PeopleWith
6:15 - 7:15 pm - NETWORKING DRINK RECEPTION
CHALLENGES & POTENTIALS OF PATIENT ENGAGEMENT
- Fostering community engagement and build trust
- Designing a patient-centric, inclusive trials
- Cultivating an inclusive research environment
- Leveraging technology and data
- Adopting regulatory requirements and institutional support
Moderator:
Panellists:
Emily Pickering, Patient Engagement in Clinical Development Service Lead, NIHR Research Delivery Network
- The WHY: diversity equity & inclusion, environmental social governance
- The WHAT: information & communication technologies (ICTs)
- The HOW: accessibility by design and shifting-left with universal design
Dr. Stephen Framil, Corporate Global Head of Accessibility, Merck & Co., INC
- Define “Diversity” in the context of EU and UK regulatory environment
- Provide information on the importance of assessing diversity based on disease area before study design and execution
- Share concrete examples of diversity in practice:
- MHRA analysis of community subgroups and their involvement in clinical trials.
- READI engagement with public’s representatives and why words matters: moving from diversity to
representativeness
Puja Myles, Director, Clinical Practice Research Datalink (CPRD), MHRA
Lea-Isabelle Proulx, Patient Voice Partner, Roche
- Why timing matters: Too early, too late, or just right?
- Striking the balance: Impact, ethics, and resources in tension
- Lessons learned so far: What real-world experience shows us
- Looking ahead: What needs to change for the future
Dr Liz Clark, Visiting Lecturer & Patient Engagement Theme Lead, King’s College London
- To Follow Shortly
Sumira Riaz, Patient Engagement/Health Psychologist Consultant, Founder, Unboxed Psychology
- The importance of data democratization
- Common challenges in clinical data review that hinders clinical trials Strategies in overcoming these challenges
- How to seamlessly integrate data from a variety of sources?
- How to improve safety review efficiencies and reduce the timeline to critical studies?
Allocated – Awaiting for details.
- Understanding patient experiences, challenges, and needs to develop solutions.
- Involving patients as equal partners in designing, developing, and evaluating healthcare solutions.
- Collaborative innovation among patients, clinicians, designers, and researchers
- Prioritize equity and inclusion by representing diverse patient voices to address disparities and tailor solutions.
- Learn about the latest technologies that can improve the efficiency and effectiveness of clinical trial design, addressing issues like increasing complexity
- Discover the principles and best practices for clinical trial design that can increase the likelihood of success, through a combination of literature analysis and practical experience
- Examine the challenges faced by patients during clinical trials and learn about potential solutions that can reduce the burden and increase the benefits for patients
Keith Berelowitz, Founder/CEO, pRxEngage Inc
Hayley Chapman, Senior Program Director, The Synergist
- Jasmine will share how BMS’s Global Purpose & Patient Experience team is embedding patient voices, carers’ insights, and community trust into every phase of development and delivery of its medicines
- Drawing from her background in nonprofit advocacy and her leadership at BMS, she’ll explore how trust building enables innovation and advances both mission and purpose
- She will spotlight tangible enterprise tools, like BMS’s Universal Patient Language (UPL) and PEER programs, that translate empathy into access, and communication into clarity.
- The talk will include lessons learned from carers, medically underserved communities, and patient collaborators who have reshaped how BMS designs, speaks, and shows up.
- Jasmine will offer a human-centric lens on trial transformation, showing how purpose-driven decisions accelerate recruitment, improve retention, and deepen real-world impact.
Jasmine Greenamyer, VP, Global Purpose & Patient Experience, Corporate Affairs, Bristol Myers Squibb
- Timing Multistakeholder Collaboration Across the Innovation Lifecycle
- How Collaboration Works: Mechanisms, Models, and Mindsets That Enable Success
- What Good Looks Like: Defining Meaningful Patient Engagement in Multistakeholder Settings
- Breaking Silos: Aligning Diverse Stakeholder Priorities to Accelerate Impact
Federica Castiglione, Sr Director Patient Advocacy & Engagement EMEA, Menarini Stemline
- Leveraging patient input and real-world data to improve relevance, safety, and efficacy
- Designing patient-centric products: key challenges and opportunities
- Redefining stakeholder roles—from early development to real-world access
- Ensuring patient voices drive not only clinical trial design but also long-term treatment adherence and outcomes in diverse populations.
Moderator:
Panelists:
Mohammed Kofi Yasimo, Vice President, Hepatitis Foundation of Ghana
Gabor Purman, Patient Advocacy Director, Kyowa Kirin
- How can we move patient engagement from a checkbox to true co-creation and shared decision-making?
- In what ways does genuine patient engagement improve health outcomes and trust?
- What are the biggest barriers that prevent meaningful patient involvement?
- How can we effectively measure the impact of patient engagement beyond satisfaction surveys?
- Are we including diverse and underserved patient voices in our engagement efforts?
- How do we ensure patients are partners and collaborators, rather than just observers or token participants?
Moderator:
Panellist:
Dominic Shadbolt, Expert Patient, Founder, theMSguide.com
